# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!


Ovarian cancer

Cancer, Ovarian
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 101-110 of 626 results.
Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study
Status: Recruiting
Last Changed: Sep 16, 2019
First Received: Sep 16, 2019
Disease(s): BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
Intervention(s): Olaparib tablets
Locations: Istituto Nazionale dei Tumori , Oncologia Medica - Dipartimento Uro-Ginecologico, Napoli, Italy
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
Status: Recruiting
Last Changed: Jan 10, 2020
First Received: Nov 27, 2017
Disease(s): Recurrent Ovarian Carcinoma
Intervention(s): Bevacizumab, Atezolizumab, Chemotherapy, Placebos
Locations: Kreiskliniken Altötting-Burghausen, Altötting, Germany
Klinikum Augsburg, Augsburg, Germany
Hochtaunus-Kliniken, Bad Homburg, Germany
Charité - Universitätsmedizin Berlin (CVK), Berlin, Germany
Helios Klinikum Berlin-Buch, Berlin, Germany
... and 56 other locations.
Intra-Peritoneal Local Anaesthetics in Ovarian Cancer
Status: Not yet recruiting
Last Changed: Aug 22, 2019
First Received: Aug 22, 2019
Disease(s): Ovarian Cancer
Intervention(s): Ropivacaine, Saline Solution
Locations: Karolinska Hospital, Solna, Stockholm, Sweden
Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.
Status: Recruiting
Last Changed: Oct 22, 2019
First Received: Aug 11, 2017
Disease(s): Hereditary Breast and Ovarian Cancer, Mutation
Intervention(s): Genetic testing
Locations: Gustave Roussy, Paris, France
Study of 6b11-OCIK Injection Treatment in Patients With Drug-resistant and Recurrence Epithelial Ovarian Cancer
Status: Not yet recruiting
Last Changed: Jun 18, 2018
First Received: May 31, 2018
Disease(s): Recurrent Platinum-Resistant Ovarian Cancer
Intervention(s): 6B11-OCIK injection
Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient
Status: Recruiting
Last Changed: Oct 15, 2018
First Received: Oct 15, 2018
Disease(s): Platinum-sensitive Relapsed Ovarian Cancer
Intervention(s): ZL-2306(nirapairb), Placebos
Locations: Cancer center of Guangzhou medical university, Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Harbin Medical university cancer hospital, Harbin, Heilongjiang, China
the first affiliated hospital of of Harbin medical university, Harbin, Heilongjiang, China
Hubei Cancer Hospital, Wuhan, Hubei, China
... and 23 other locations.
Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer
Status: Recruiting
Last Changed: Feb 13, 2020
First Received: Nov 15, 2018
Disease(s): Cancer, Ovarian Cancer
Intervention(s): CPC634 (CriPec® docetaxel)
Locations: Universitaire Ziekenhuizen Leuven, Leuven, Belgium
CHU de Liège, Liège, Belgium
University Medical Center Groningen, Groningen, Netherlands
Dijklander Hospital, Hoorn, Netherlands
Radboud University Medical Center, Nijmegen, Netherlands
... and 4 other locations.
ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
Status: Not yet recruiting
Last Changed: Feb 13, 2020
First Received: Feb 13, 2020
Disease(s): Advanced Solid Tumors (Excluding Prostate Cancer), Ovarian Cancer
Intervention(s): BAY1895344, Niraparib
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Cleveland Clinic, Cleveland, Ohio, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma
Status: Recruiting
Last Changed: Dec 05, 2019
First Received: Oct 14, 2016
Disease(s): Ovarian Cancer
Intervention(s): OncoImmunome
Locations: UConn Health, Farmington, Connecticut, United States
Acupressure for Fatigue in Ovarian Cancer Survivors
Status: Recruiting
Last Changed: Nov 27, 2019
First Received: Dec 04, 2018
Disease(s): Fatigue, Ovarian Cancer
Intervention(s): Acupressure, Sham acupressure, Standard of Care
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States